tetano
Editor, Senior Moderator
Vaccine. 2017 Aug 19. pii: S0264-410X(17)31096-4. doi: 10.1016/j.vaccine.2017.08.029. [Epub ahead of print]
[h=1]Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.[/h] Levin MJ[SUP]1[/SUP], Buchwald UK[SUP]2[/SUP], Gardner J[SUP]3[/SUP], Martin J[SUP]3[/SUP], Stek JE[SUP]3[/SUP], Brown E[SUP]3[/SUP], Popmihajlov Z[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] Randomized, blinded, placebo-controlled trial to evaluate the safety and immunogenicity of ZOSTAVAX? (ZV) administered concomitantly with quadrivalent inactivated influenza vaccine (IIV4) in adults≥50years of age (NCT02519855).
[h=4]METHODS:[/h] Overall, 440 participants were randomized into the Concomitant Group (CG) and 442 into the Sequential Group (SG). The CG received ZV and IIV4 at separate injection sites on Day 1 and matching placebo at Week 4. The SG received placebo and IIV4 (2015-2016 influenza season) at separate injection sites on Day 1 and ZV at Week 4.
[h=4]IMMUNOGENICITY ENDPOINTS:[/h] Varicella-zoster virus (VZV) antibody geometric mean titer (GMT) and geometric mean fold-rise (GMFR) from baseline to 4weeks postvaccination, measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and adjusted for age and prevaccination titer. Influenza strain-specific GMT at baseline and 4weeks postvaccination was measured by hemagglutination inhibition (HAI) assay.
[h=4]SAFETY ENDPOINTS:[/h] Injection-site and systemic adverse experiences (AEs) within 28days following any vaccination and serious AEs throughout the study.
[h=4]RESULTS:[/h] The adjusted VZV antibody GMT ratio (CG/SG) was 0.87 (95%CI: 0.80, 0.95), meeting the prespecified noninferiority criterion. The VZV antibody GMFR in the CG was 1.9 (95%CI: 1.76, 2.05), meeting the acceptability criterion. Influenza antibody GMT ratios for A/H1N1, A/H3N2, B/Yamagata and B/Victoria were 1.02 (95%CI: 0.88, 1.18), 1.10 (95%CI: 0.94, 1.29), 1.00 (95%CI: 0.88, 1.14), and 0.99 (95%CI: 0.87, 1.13), respectively. The frequency of vaccine-related injection-site and systemic AEs was comparable between groups. No vaccine-related serious AE was observed.
[h=4]CONCLUSION:[/h] The concomitant administration of ZV and IIV4 to adults≥50years of age induced VZV-specific and influenza-specific antibody responses that were comparable to those following administration of either vaccine alone, and was generally well tolerated.
Copyright ? 2017 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Herpes zoster; Immunogenicity; Safety; Tolerability; Zoster vaccine
PMID: 28830693 DOI: 10.1016/j.vaccine.2017.08.029
[h=1]Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.[/h] Levin MJ[SUP]1[/SUP], Buchwald UK[SUP]2[/SUP], Gardner J[SUP]3[/SUP], Martin J[SUP]3[/SUP], Stek JE[SUP]3[/SUP], Brown E[SUP]3[/SUP], Popmihajlov Z[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] Randomized, blinded, placebo-controlled trial to evaluate the safety and immunogenicity of ZOSTAVAX? (ZV) administered concomitantly with quadrivalent inactivated influenza vaccine (IIV4) in adults≥50years of age (NCT02519855).
[h=4]METHODS:[/h] Overall, 440 participants were randomized into the Concomitant Group (CG) and 442 into the Sequential Group (SG). The CG received ZV and IIV4 at separate injection sites on Day 1 and matching placebo at Week 4. The SG received placebo and IIV4 (2015-2016 influenza season) at separate injection sites on Day 1 and ZV at Week 4.
[h=4]IMMUNOGENICITY ENDPOINTS:[/h] Varicella-zoster virus (VZV) antibody geometric mean titer (GMT) and geometric mean fold-rise (GMFR) from baseline to 4weeks postvaccination, measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and adjusted for age and prevaccination titer. Influenza strain-specific GMT at baseline and 4weeks postvaccination was measured by hemagglutination inhibition (HAI) assay.
[h=4]SAFETY ENDPOINTS:[/h] Injection-site and systemic adverse experiences (AEs) within 28days following any vaccination and serious AEs throughout the study.
[h=4]RESULTS:[/h] The adjusted VZV antibody GMT ratio (CG/SG) was 0.87 (95%CI: 0.80, 0.95), meeting the prespecified noninferiority criterion. The VZV antibody GMFR in the CG was 1.9 (95%CI: 1.76, 2.05), meeting the acceptability criterion. Influenza antibody GMT ratios for A/H1N1, A/H3N2, B/Yamagata and B/Victoria were 1.02 (95%CI: 0.88, 1.18), 1.10 (95%CI: 0.94, 1.29), 1.00 (95%CI: 0.88, 1.14), and 0.99 (95%CI: 0.87, 1.13), respectively. The frequency of vaccine-related injection-site and systemic AEs was comparable between groups. No vaccine-related serious AE was observed.
[h=4]CONCLUSION:[/h] The concomitant administration of ZV and IIV4 to adults≥50years of age induced VZV-specific and influenza-specific antibody responses that were comparable to those following administration of either vaccine alone, and was generally well tolerated.
Copyright ? 2017 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Herpes zoster; Immunogenicity; Safety; Tolerability; Zoster vaccine
PMID: 28830693 DOI: 10.1016/j.vaccine.2017.08.029